Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects

A promising strategy for cancer immunotherapy is to disrupt key pathways regulating immune tolerance, such as cytotoxic T lymphocyte–associated protein 4 (CTLA-4). However, the determinants of response to anti–CTLA-4 mAb treatment remain incompletely understood. In murine models, anti–CTLA-4 mAbs al...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ruocco, Maria Grazia, Pilones, Karsten A., Kawashima, Noriko, Cammer, Michael, Huang, Julie, Babb, James S., Liu, Mengling, Formenti, Silvia C., Dustin, Michael L., Demaria, Sandra
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3461908/
https://ncbi.nlm.nih.gov/pubmed/22945631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI61931
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados